Pall Corporation

Our Breathing Filter Product Family Is Now SARS-CoV-2 Validated for European Countries Under CE Mark*

One of the most frequently asked questions about our breathing system filters since early 2020 has been: “Do your breathing system filters retain SARS-CoV-2?” It can now be most definitively answered: “Yes, they can!”

Our Breathing Filters Retain More Than 99.999% of Aerosolized SARS-CoV-2

Ultipor® 25 (BB25)


Ultipor 100 (BB100)

Ultipor 25 (BB25)
  • High performance mechanical, hydrophobic filter
  • Small housing contour
  • Extensive documentation
  • SARS-CoV-2 retention of > 99.999%
  • High performance mechanical, hydrophobic filter
  • High retention capacity
  • Extended service life
  • SARS-CoV-2 retention of > 99.999%
Ultipor 100 (BB100)
  • High performance mechanical, hydrophobic filter
  • Optimal humidification
  • Compatible with nebulization
  • SARS-CoV-2 retention of > 99.999%

*These products have not been cleared for this claim by the FDA

Our Breathing Filters Meet the Highest Performance Standards in The Prevention of Cross-Contamination

We have subjected representative samples of our Ultipor 25, Ultipor 100 and BB50TE to vigorous testing, challenging each filter with a virus load of > 100 million with the heat inactivated actual SARS-CoV-2 virus.

We can confirm that all filters consistently retain more than 99.999% of the aerosolized virus.

This result is in alignment with earlier work, which demonstrated >99.999% retention of other airborne human pathogenic viruses (e.g., Influenza A) and bacteria (e.g., Mycobacterium tuberculosis). Our Breathing System Filters contain a highly efficient hydrophobic filter medium and therefore also showed 100% retention of liquid-borne human pathogenic viruses (e.g., HIV and Hepatitis C).

We are happy to provide this additional piece of evidence to you in support of choosing the best product for the protection of patients, staff and equipment.

To Receive More Information & Free Samples Contact Us!

All fields required